Journal article
Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference
RC Bast, UA Matulonis, AK Sood, AA Ahmed, AE Amobi, FR Balkwill, M Wielgos-Bonvallet, DDL Bowtell, JD Brenton, JS Brugge, RL Coleman, GF Draetta, K Doberstein, RI Drapkin, MA Eckert, RP Edwards, KM Elias, D Ennis, A Futreal, DM Gershenson Show all
Cancer | WILEY | Published : 2019
DOI: 10.1002/cncr.32004
Abstract
Substantial progress has been made in understanding ovarian cancer at the molecular and cellular level. Significant improvement in 5-year survival has been achieved through cytoreductive surgery, combination platinum-based chemotherapy, and more effective treatment of recurrent cancer, and there are now more than 280,000 ovarian cancer survivors in the United States. Despite these advances, long-term survival in late-stage disease has improved little over the last 4 decades. Poor outcomes relate, in part, to late stage at initial diagnosis, intrinsic drug resistance, and the persistence of dormant drug-resistant cancer cells after primary surgery and chemotherapy. Our ability to accelerate p..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
Robert C. Bast, Jr, is supported by National Cancer Institute grants P50 CA083639, P50 CA217685, and U01 CA200462, Cancer Prevention and Research Institute of Texas RP101382 and RP160145, and the National Foundation of Cancer Research. Ursula A. Matulonis is supported by the Breast Cancer Research Foundation. Anil K. Sood is supported by National Cancer Institute grant P50 CA217685 and the American Cancer Society Research Professor Award. Robert L. Coleman is supported by Cancer Prevention Research Institute of Texas grants RP210214 and RP160145. David G. Huntsman is supported by National Cancer Institute grant R01 CA19567001. Elise C. Kohn is supported by the Cancer Therapy Evaluation Program of the National Cancer Institute. Gordon B. Mills is supported by National Cancer Institute grant P50 CA217685, the Ovarian Cancer Research Foundation, the Prospect Creek Foundation, and the Adelson Medical Research Foundation. Francesmary Modugno is supported by the University School of Medicine Dean's Faculty Advancement Fund. Rugang Zhang is supported by National Cancer Institute grants R01 CA163377 and R01 CA202919.